MATERIAL SAFETY DATA SHEET

Product Name: Bupivacaine Hydrochloride and Epinephrine Injection, USP

1. CHEMICAL PRODUCT AND COMPANY INFORMATION

Manufacturer Name: Hospira, Inc.
And Address: 275 North Field Drive
Lake Forest, Illinois 60045
USA

Emergency Telephone:
- CHEMTREC: 800 424-9300
- Hospira, Inc.: 224 212-2055

Product Name: Bupivacaine Hydrochloride and Epinephrine Injection, USP
Synonyms: None

2. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Chemical Formula</th>
<th>Approximate Percent by Weight</th>
<th>CAS Number</th>
<th>RTECS Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bupivacaine Hydrochloride</td>
<td>0.25-0.75</td>
<td>14252-80-3</td>
<td>TK6125000</td>
<td></td>
</tr>
<tr>
<td>Epinephrine</td>
<td>0.0005</td>
<td>51-43-4</td>
<td>DO2625000</td>
<td></td>
</tr>
<tr>
<td>Water</td>
<td>99</td>
<td>7732-18-5</td>
<td>ZC0110000</td>
<td></td>
</tr>
</tbody>
</table>

3. HAZARD INFORMATION

Emergency Overview: In clinical use, this material is used to cause local or regional anesthesia or analgesia for surgical procedures. Bupivacaine hydrochloride is considered to be highly toxic by ingestion. Epinephrine is a potent drug and is considered to be highly toxic by ingestion and by skin contact. Target organs include the skin, nervous system, central nervous system, cardiovascular system and respiratory system.

Occupational Exposure Potential: Information on the absorption of this compound via ingestion, inhalation or skin contact is not available. Avoid liquid aerosol generation and skin contact with solution.

Signs and Symptoms: No signs or symptoms from occupational exposure are known. Clinical data suggests the following: numbness, restlessness, anxiety, dizziness, ringing in the ear, visual impairment, tremor, convulsions, decreased blood pressure, slow heart rate, cardiac changes, mood changes, cardiac arrest.

Medical Conditions Aggravated by Exposure: Data suggest pre-existing ailments in the following organs: central nervous system and cardiovascular system. Hypersensitivity to the material and/or similar materials.
4. FIRST AID MEASURES

Eye Contact: Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

Skin Contact: Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

Inhalation: Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic / supportive care as necessary.

Ingestion: Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic / supportive care as necessary.

5. FIRE FIGHTING MEASURES

Flammability: Non-flammable.

Fire & Explosion Hazard: None

Extinguishing Media: Use extinguishing media appropriate for the underlying cause of fire.

Special Fire Fighting Procedures: No special provisions required beyond normal fire fighting equipment such as flame and chemical resistant clothing and self contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Spill Cleanup and Disposal: Absorb liquid with suitable material and clean affected area with soap and water. Dispose of materials according to the applicable federal, state, or local regulations.

7. HANDLING AND STORAGE

Handling: No special handling required.

Storage: No special storage required for hazard control. For product protection store at controlled room temperature of 15-30°C (59-86°F). Protect from light.

Special Precautions: Protect from freezing and extreme heat.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Exposure Guidelines

<table>
<thead>
<tr>
<th>Component</th>
<th>OSHA-PEL</th>
<th>ACGIH-TLV</th>
<th>Hospira EEL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bupivacaine Hydrochloride</td>
<td>8 hr TWA: Not</td>
<td>8 hr TWA Not</td>
<td>8 hr TWA: 50 mcg/m³</td>
</tr>
<tr>
<td></td>
<td>Established</td>
<td>Established</td>
<td>STEL 500 mcg/m³</td>
</tr>
<tr>
<td>Epinephrine</td>
<td>8 hr TWA: Not</td>
<td>8 hr TWA Not</td>
<td>8 hr TWA: 1 mcg/m³</td>
</tr>
<tr>
<td></td>
<td>Established</td>
<td>Established</td>
<td>STEL: 20 mcg/m³</td>
</tr>
</tbody>
</table>

Notes: OSHA PEL: US Occupational Safety and Health Administration – Permissible Exposure Limit
ACGIH TLV: American Conference of Governmental Industrial Hygienists – Threshold Limit Value.
EEL: Employee Exposure Limit.
TWA: 8 hour Time Weighted Average.
STEL: 15-minute Short Term Exposure Limit.
Product Name: Bupivacaine Hydrochloride and Epinephrine Injection, USP

Respiratory Protection
Respiratory protection is not needed during normal product use.

Skin Protection
If solution contact with unprotected skin is likely, use of impervious gloves is a prudent practice.

Eye Protection
Eye protection is not required during expected product use conditions but may be warranted should a splash potential exist.

Engineering Controls
Engineering controls are not needed during normal product use conditions.

9. PHYSICAL/CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance/Physical State</td>
<td>Clear liquid</td>
</tr>
<tr>
<td>Odor</td>
<td>None</td>
</tr>
<tr>
<td>Boiling Point</td>
<td>Approximately that of water (100 °C, 212 °F).</td>
</tr>
<tr>
<td>Freezing Point</td>
<td>Approximately that of water (0°C, 32 °F).</td>
</tr>
<tr>
<td>Vapor Pressure</td>
<td>Approximately that of water (17.5 mm Hg at 20 °C).</td>
</tr>
<tr>
<td>Vapor Density (Air=1)</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Evaporation Rate</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Bulk Density</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Specific Gravity</td>
<td>1.004 gm/L at 25°C.</td>
</tr>
<tr>
<td>Solubility</td>
<td>Aqueous solution</td>
</tr>
<tr>
<td>pH</td>
<td>3.5 – 5.5</td>
</tr>
</tbody>
</table>

10. STABILITY AND REACTIVITY

Chemical Stability
Stable under standard use and storage conditions.

Incompatibilities
None

Hazardous Decomposition Products
Oxides of NOx

Hazardous Polymerization
None

11. TOXICOLOGICAL INFORMATION:

<table>
<thead>
<tr>
<th>Ingredient(s)</th>
<th>Percent</th>
<th>Test Type</th>
<th>Value</th>
<th>Units</th>
<th>Species</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bupivacaine Hydrochloride</td>
<td>100</td>
<td>LD50</td>
<td>18</td>
<td>mg/kg</td>
<td>Rabbits</td>
</tr>
<tr>
<td>Epinephrine</td>
<td>100</td>
<td>LD50</td>
<td>24-50</td>
<td>mg/kg</td>
<td>Rats, Mice</td>
</tr>
</tbody>
</table>

LD50 is the dosage producing 50% mortality.
Product contains less than 1%Bupivacaine Hydrochloride and less than 0.001% Epinephrine.

Mutagenicity
Not determined.

Target Organ Effects
Bupivacaine hydrochloride is a local anesthetic that produces anesthesia (numbness) by blockage of nerve conduction and can also adversely affect the central nervous system and heart. Produced decreased survival in rat pups and fetal death in rabbits at 5 and 9 times the maximum recommended daily dose, respectively, and has the potential to produce fetal toxicity in humans.
Product Name: Bupivacaine Hydrochloride and Epinephrine Injection, USP

Target Organ Effects (continued)

Epinephrine is a naturally occurring sympathomimetic amine that stimulates the sympathetic nervous system. Can produce irritation, pigment deposition, a reduction of intraocular pressure and a reduction in visual acuity to the eyes. Intranasal use can lead to rebound congestion while injection can lead to tissue necrosis due to local constriction of blood vessels. Use of epinephrine by pregnant women may delay labor by retarding uterine contractions and case fetal anoxia. Has produced teratogenic effects in animals at 25 times the clinical dose and some mutagenic effect in bioassays. Nasal changes were produced by epinephrine hydrochloride in long-term inhalation studies in rats and mice at concentrations of 1.5 mg/m3 or more.

12. ECOLOGICAL INFORMATION:

Aquatic Toxicity

Not determined.

13. DISPOSAL CONSIDERATIONS:

Waste Disposal

Disposal should be performed in accordance with the federal, state or local regulatory requirements.

Container Handling and Disposal

Dispose of container and unused contents in accordance with federal, state, and local regulations.

14. TRANSPORTATION INFORMATION

DOT

Not Regulated

Notes:

DOT - US Department of Transportation Regulations

15. REGULATORY INFORMATION

TSCA Status

Bupivacaine Hydrochloride and Epinephrine are not listed on the TSCA inventory.

CERCLA Status

Not Regulated

SARA Status

Not Regulated

RCRA Status

Not Regulated

PROP 65 (Calif.)

Not Regulated

Notes:

TSCA Toxic Substance Control Act
CERCLA, US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act
SARA Superfund Amendments and Reauthorization Act
RCRA US EPA, Resource Conservation and Recovery Act
Prop 65, California Proposition 65

16. OTHER INFORMATION:

MSDS Coordinator

Global Occupational Toxicology

Date Prepared

September 15, 2005

Date Revised

October 21, 2008

Disclaimer:

The information and recommendations contained herein are based upon tests believed to be reliable. However, Hospira does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. Hospira assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.